In This Article:
-
Total Sales Growth: 9.5% increase at constant exchange rates, reaching EUR1.6 billion.
-
Core Operating Margin: 32.4%.
-
Free Cash Flow: EUR394 million, a 5.9% increase.
-
Core Operating Income: EUR538 million, a 2.8% increase.
-
Somatuline Sales Decline: 1% decline overall; 6.3% decline in North America.
-
Cabometyx Sales Growth: 17% increase.
-
Onivyde Sales Growth: 25% increase.
-
Bylvay Annualization: Over EUR100 million.
-
SG&A Costs: Increased by 4%, with a ratio to sales at 34.6%.
-
R&D Costs: Increased by 11%, reaching 19.5% of total sales.
-
Available Firepower for External Innovation: Over EUR2 billion.
-
Upgraded 2024 Guidance: Total sales growth expected to be more than 7% at constant exchange rates.
Release Date: July 25, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Ipsen SA (IPSEF) reported a strong financial performance with total sales growth of 9.5% in the first half of the year.
-
The company achieved a core operating margin of 32.4%, reflecting efficient cost management.
-
Ipsen SA (IPSEF) generated free cash flow of EUR394 million, indicating strong cash generation capabilities.
-
Regulatory successes included FDA approvals for Onivyde in first-line pancreatic cancer and Iqirvo in second-line PBC.
-
The company expanded its pipeline with in-licensing of ex-US rights to savolitinib in pediatric oncology and executed multiple early-stage transactions in oncology and neuroscience.
Negative Points
-
Somatuline sales in North America fell by 6.3% due to adverse US pricing, and a sharp decline is anticipated in the second half due to increased generic penetration.
-
The gross margin decreased by 1.6 points, driven by an unfavorable sales mix and higher royalty payments.
-
R&D costs increased by 11%, impacting the overall profitability despite strong sales growth.
-
The company faces potential challenges with the erosion of Somatuline sales due to generic competition, particularly in the US.
-
There is uncertainty regarding the impact of potential market changes, such as the removal of Ocaliva, which could affect Iqirvo's market dynamics.
Q & A Highlights
Q: Can you provide insights on the expected erosion of Somatuline sales in the second half of the year and how it factors into the 2024 guidance? A: David Loew, CEO, explained that they anticipate an acceleration of Somatuline erosion due to increased generic competition, particularly in the US. This expectation is already factored into their 2024 guidance, assuming supply recovery in Europe and stronger erosion in the US.